Clinical Trial Update: To Evaluate the Safety and Tolerability of Carbognilumab Combined With Chemotherapy as the First-line Treatment for Patients With KEAP1 Mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the safety and tolerability of carbognilumab with chemotherapy as first-line treatment for KEAP1-mutated advanced or postoperative recu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Carbognilumab (carbognilumab)

Snippet

Sponsor: Guangzhou Institute of Respiratory Disease | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: UNKNOWN